Kalomiris E L, Bourguignon L Y
Department of Anatomy and Cell Biology, School of Medicine, University of Miami, Florida 33101.
J Biol Chem. 1989 May 15;264(14):8113-9.
In this study, several complementary techniques have been used to investigate the involvement of a protein kinase C (PKC) molecule in the plasma membrane-cytoskeleton interactions that occur in mouse T-lymphoma cells. Our data indicate that the lymphoma plasma membrane contains a 78-kDa polypeptide that exists in a complex with one of the major transmembrane glycoproteins, GP85 (a wheat germ agglutinin-binding protein). This membrane-associated 78-kDa protein appears to have PKC-like properties based on the following criteria: 1) it cross-reacts with a specific antibody raised against brain PKC; 2) it has a pI of 5.6-5.8, which is similar to that of the PKC described previously in other cell types; and 3) it displays characteristic PKC enzymatic activity by phosphorylating histone H1 in a Ca2+- and phospholipid-dependent manner. Double immunocytochemical staining experiments reveal that the lymphoma PKC-like molecules translocate from the cytoplasm to the cell membrane and accumulate directly underneath receptor capped structures following addition of various ligands. Studies we have done to identify the cellular substrate(s) of the lymphoma plasma membrane-associated PKC have shown that GP85 is preferentially phosphorylated in isolated membrane preparations following addition of the PKC activator, TPA (phorbol-12-O-tetradecanoyl-phorbol 13-acetate), but not the biologically inactive TPA analogue, 4 alpha-PDD (4 alpha-phorbol 12,13-didecanoate). In addition, we have found that GP85 can be phosphorylated by purified brain protein kinase C. Analysis of the resulting phosphoamino acids indicates that phosphorylation of GP85 occurs primarily at serine residues, occurs in minor amounts (approximately 5%) at threonine residues, and does not occur at tyrosine residues. These data indicate that the lymphoma GP85 is a substrate for PKC. Furthermore, we have established that phosphorylation of GP85 by PKC enhances its binding affinity with the membrane linker molecule, ankyrin. These findings suggest that PKC-mediated phosphorylation of GP85 may be an important part of the lymphoma plasma membrane-cytoskeleton interaction.
在本研究中,我们运用了多种互补技术来探究蛋白激酶C(PKC)分子在小鼠T淋巴瘤细胞中发生的质膜 - 细胞骨架相互作用中的作用。我们的数据表明,淋巴瘤质膜含有一种78 kDa的多肽,它与一种主要的跨膜糖蛋白GP85(一种麦胚凝集素结合蛋白)形成复合物存在。基于以下标准,这种与膜相关的78 kDa蛋白似乎具有PKC样特性:1)它与针对脑PKC产生的特异性抗体发生交叉反应;2)其pI为5.6 - 5.8,这与先前在其他细胞类型中描述的PKC相似;3)它通过以Ca2 +和磷脂依赖性方式磷酸化组蛋白H1表现出典型的PKC酶活性。双重免疫细胞化学染色实验表明,在添加各种配体后,淋巴瘤PKC样分子从细胞质转移到细胞膜,并直接聚集在受体帽结构下方。我们为鉴定淋巴瘤质膜相关PKC的细胞底物所做的研究表明,在添加PKC激活剂佛波酯(TPA,phorbol - 12 - O - tetradecanoyl - phorbol 13 - acetate)后,分离的膜制剂中GP85优先被磷酸化,但生物活性无的TPA类似物4α - PDD(4α - phorbol 12,13 - didecanoate)则不会。此外,我们发现GP85可被纯化的脑蛋白激酶C磷酸化。对所得磷酸氨基酸的分析表明,GP85的磷酸化主要发生在丝氨酸残基上,少量(约5%)发生在苏氨酸残基上,而酪氨酸残基上不发生磷酸化。这些数据表明淋巴瘤GP85是PKC的底物。此外,我们已经确定PKC对GP85的磷酸化增强了其与膜连接分子锚蛋白的结合亲和力。这些发现表明PKC介导的GP85磷酸化可能是淋巴瘤质膜 - 细胞骨架相互作用的重要组成部分。